Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer

Archives of Surgery

Volumn 136, Issue 1, 2001, Pages 105-112

  Guadagni, S ^a   Fiorentini, G ^a   Palumbo, G ^a   Valenti, M ^a   Russo, F ^b   Cantore, M ^a   Deraco, M ^c   Vaglini, M ^c   Amicucci, G ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ATROPINE; CEFOTAXIME; FENTANYL CITRATE; FLUOROURACIL; GLYCERYL TRINITRATE; HEPARIN CALCIUM; ISOFLURANE; MITOMYCIN C; NITROUS OXIDE; PROMETHAZINE; PROPOFOL; SUXAMETHONIUM; URAPIDIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BALLOON CATHETER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INFUSION; FEMALE; HUMAN; HYPOXIA; MALE; MULTIMODALITY CANCER THERAPY; PELVIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; RECURRENT CANCER;

EID: 0035154896     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.136.1.105     Document Type: Article

References (56)

1. Local recurrence of rectal adenocarcinoma after "curative" surgery with and without preoperative radiotherapy
2. Definition of local recurrence after surgery for rectal carcinoma
3. Surgical management of locally recurrent rectal cancer
4. Improved survival with preoperative radiotherapy in resectable rectal cancer
5. Treatment of local recurrence of rectal cancer
6. Patterns of pelvic recurrence following definitive resections of rectal cancer
7. Pelvic resection of recurrent rectal cancer
8. Curative reoperations for locally recurrent rectal cancer
9. Significance of local recurrence of rectal cancer as a local or disseminated disease
10. Sacropelvic resection and intraoperative electron irradiation in the management of recurrent anorectal cancer
11. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma
12. High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer
13. Isolated locally recurrent rectal cancer: A review of incidence, presentation, and management
14. Complete remission after radiotherapy for recurrent rectal cancer
15. Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery
16. Results of external beam irradiation for rectal carcinomas locally recurrent after local excision or electrocoagulation
17. Radiation therapy for unresectable rectal cancer
18. Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer
19. Radiotherapy treatment for isolated loco-regional recurrence of rectosigmoid cancer following definitive surgery: Peter MacCallum Cancer Institute experience, 1981-1990
20. Treatment of locally recurrent rectal carcinoma: Results and prognostic factors
21. Palliative reirradiation for recurrent rectal cancer
22. Intra-arterial perfusion therapy with 5-fluorouracil in patients with metastatic colorectal carcinoma and intractable pelvic pain
23. Palliation of pelvic recurrence of colorectal cancer with intraarterial 5-fluouracil and mitomycin
24. Intraarterial chemotherapy and hypertermia for pain control in patients with recurrent rectal cancer
25. Treatment of colorectal cancer pelvic recurrences with hypogastric intra-arterial 5-fluorouracil by means of totally implantable port systems
26. Palliation of recurrent rectal cancer with intraarterial mitomycin C/5-fluorouracil via Jet Port aortic bifurcation catheter
27. Pelvic intraarterial mitomycin C infusion in previously treated patients with metastatic, unresectable pelvic colorectal cancer and angiographic determination of tumor vascularity
28. Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer
29. Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-FU
30. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit
31. Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion
32. Isolated pelvic perfusion for the treatment of unresectable primary or recurrent rectal cancer
33. Treatment of malignant pelvic tumors by extracorporeal perfusion with chemotherapeutic agents
34. Value of perfusion in pelvic surgery
35. Abdominal perfusion for cancer chemotherapy with hypothermia and hyperthermia
36. Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer
37. Regional perfusion of the pelvis: Consideration of the "leakage" problem
38. Perfusion chemotherapy for gynecological malignancy
39. The use of intravascular balloon catheters for isolation of the pelvic vascular bed during pump-oxigenator perfusion of cancer chemotherapeutic agents
40. Regional perfusion of pelvis and abdomen by an indirect technique
41. Isolated pelvic perfusion for unrectable cancer using a balloon occlusion technique
42. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the ballon-occlusion technique
43. Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer
44. A percutaneous aortic "stop-flow" infusion technique for regional cytotoxic therapy of the abdomen and pelvis
45. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells
46. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro
47. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: A pilot study of patients with recurrent unresectable rectal cancer
48. Prospective correlative chemosensitivity testing in high-dose intraarterial chemoterapy for liver metastases
49. Mitomycin C in biological fluids: Comparison of disk and cartridge solid-phase extraction and quantitation by HPLC in human plasma and ultrafiltrate
50. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer
51. Extracorporeal hemofiltration: A model for decreasing systemic drug exposure with intra-arterial chemotherapy
52. New findings in the pharmacokinetic, metabolic and drug-resistance aspects of mitomycin C
53. Actions of heparin that may affect the malignant process
54. Intrahepatic artery high-dose chemotherapy with concomitant post-hepatic venous blood detoxification: Comparison between drug removal systems
55. High dose MMC: Aortic stopflow infusion (ASI) with versus without chemofiltration: A comparison of toxic side effects